Drug class
Carbidopa prodrug; pyridoxine-independent peripheral dopa-decarboxylase inhibitor component of VYALEV
Mechanism of action
Foscarbidopa is a phosphate prodrug converted to carbidopa, which inhibits peripheral aromatic L-amino-acid decarboxylase and reduces peripheral conversion of levodopa to dopamine, increasing levodopa availability to the brain. It is used as part of the fixed foscarbidopa/foslevodopa combination.
General use cases
- Component of the fixed combination VYALEV (foscarbidopa/foslevodopa) for treatment of motor fluctuations in adults with advanced Parkinson disease; not a stand-alone approved indication
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
